

AD \_\_\_\_\_

GRANT NUMBER DAMD17-97-1-7048

TITLE: Characterization of BRCA2 Transcriptional Regulation

PRINCIPAL INVESTIGATOR: Fergus J. Couch, Ph.D.

CONTRACTING ORGANIZATION: Mayo Clinic and Foundation  
Rochester, Minnesota 55905

REPORT DATE: August 1998

TYPE OF REPORT: Annual

PREPARED FOR: U.S. Army Medical Research and Materiel Command  
Fort Detrick, Maryland 21702-5012

DISTRIBUTION STATEMENT: Approved for public release;  
distribution unlimited

The views, opinions and/or findings contained in this report are those of the author(s) and should not be construed as an official Department of the Army position, policy or decision unless so designated by other documentation.

# REPORT DOCUMENTATION PAGE

Form Approved  
OMB No. 0704-0188

Public reporting burden for this collection of information is estimated to average 1 hour per response, including the time for reviewing instructions, searching existing data sources, gathering and maintaining the data needed, and completing and reviewing the collection of information. Send comments regarding this burden estimate or any other aspect of this collection of information, including suggestions for reducing this burden, to Washington Headquarters Services, Directorate for Information Operations and Reports, 1215 Jefferson Davis Highway, Suite 1204, Arlington, VA 22202-4302, and to the Office of Management and Budget, Paperwork Reduction Project (0704-0188), Washington, DC 20503.

1. AGENCY USE ONLY (Leave blank)		2. REPORT DATE August 1998	3. REPORT TYPE AND DATES COVERED Annual (1 Aug 97 - 31 Jul 98)	
4. TITLE AND SUBTITLE Characterization of BRCA2 Transcriptional Regulation			5. FUNDING NUMBERS DAMD17-97-1-7048	
6. AUTHOR(S) Couch, Fergus J., Ph.D.				
7. PERFORMING ORGANIZATION NAME(S) AND ADDRESS(ES) Mayo Clinic and Foundation Rochester, Minnesota 55905			8. PERFORMING ORGANIZATION REPORT NUMBER	
9. SPONSORING / MONITORING AGENCY NAME(S) AND ADDRESS(ES) U.S. Army Medical Research and Materiel Command Fort Detrick, Maryland 21702-5012			10. SPONSORING / MONITORING AGENCY REPORT NUMBER	
11. SUPPLEMENTARY NOTES  <div style="text-align: right; font-size: 2em; font-weight: bold;">19990820 050</div>				
12a. DISTRIBUTION / AVAILABILITY STATEMENT Approved for public release; distribution unlimited			12b. DISTRIBUTION CODE	
13. ABSTRACT (Maximum 200 words)				
14. SUBJECT TERMS Breast Cancer			15. NUMBER OF PAGES 6	
			16. PRICE CODE	
17. SECURITY CLASSIFICATION OF REPORT Unclassified	18. SECURITY CLASSIFICATION OF THIS PAGE Unclassified	19. SECURITY CLASSIFICATION OF ABSTRACT Unclassified	20. LIMITATION OF ABSTRACT Unlimited	

## FOREWORD

Opinions, interpretations, conclusions and recommendations are those of the author and are not necessarily endorsed by the U.S. Army.

\_\_\_\_ Where copyrighted material is quoted, permission has been obtained to use such material.

\_\_\_\_ Where material from documents designated for limited distribution is quoted, permission has been obtained to use the material.

\_\_\_\_ Citations of commercial organizations and trade names in this report do not constitute an official Department of Army endorsement or approval of the products or services of these organizations.


\_\_\_\_ In conducting research using animals, the investigator(s) adhered to the "Guide for the Care and Use of Laboratory Animals," prepared by the Committee on Care and use of Laboratory Animals of the Institute of Laboratory Resources, national Research Council (NIH Publication No. 86-23, Revised 1985).

✓ \_\_\_\_ For the protection of human subjects, the investigator(s) adhered to policies of applicable Federal Law 45 CFR 46.

✓ \_\_\_\_ In conducting research utilizing recombinant DNA technology, the investigator(s) adhered to current guidelines promulgated by the National Institutes of Health.

✓ \_\_\_\_ In the conduct of research utilizing recombinant DNA, the investigator(s) adhered to the NIH Guidelines for Research Involving Recombinant DNA Molecules.

\_\_\_\_ In the conduct of research involving hazardous organisms, the investigator(s) adhered to the CDC-NIH Guide for Biosafety in Microbiological and Biomedical Laboratories.



PI - Signature

2/99

Date

## TABLE OF CONTENTS

Cover

SF 298 (Report Documentation Page)

Foreword

Table of Contents

Overview 5

Experimental Results 5

Future Experiments 6

## Annual Report DAMD17-97-1-7048

### Overview

The purpose of this award is to study the transcriptional regulation of the BRCA2 breast cancer predisposition gene with the goal of identifying agents capable of modulating BRCA2 expression.

The grant was originally awarded to the University of Pennsylvania, where early studies took place. Initially, reagents for transcriptional studies were generated. The promoter was cloned into luciferase reporter vectors, and expression constructs of BRCA2, BRCA1, p53, p21, p27 and a number of other cell cycle regulating genes were generated. Early reporter experiments utilized these constructs in MCF-7 breast cancer cells. Transfection efficiency was normalized using a LacZ expressing pCH110 construct. Studies demonstrated that BRCA2, BRCA1, p53, p21, p27, E2F, SV40-T had no effect on BRCA2 expression. Thus BRCA2 would not seem to be directly modulated by regulators of the cell cycle.

In November 1997, I moved to the Mayo Clinic and initiated transfer of the grant. The transfer request has been considered and approved and the grant has now been awarded to the Mayo Clinic. Details of this process are available from Kathy Dunn and Kathy Smith. However, the process of transfer took approximately 14 months to complete. No financing was available at the Mayo Clinic to support this research and as a result only a minor amount of further work has been performed. Since notification of the award was made the Mayo Clinic has provided funds to re-initiate the research. Thus, some new work has been completed since December 1998, and this is outlined below.

### Experimental Results

- 1) The specific aims of the project have not changed. No manuscripts regarding the transcriptional regulation of BRCA2 have been published.
- 2) As previously reported, specific aim #1 has been completed. Mutation screening of high risk breast cancer patients for promoter mutations has failed to identify any disease associated variants.
- 3) Several of the previous promoter constructs were found to contain errors. These constructs were re-engineered. A number of novel constructs have also been engineered in an effort to generate a series of deletion constructs crossing the entire 7kb BRCA2 promoter. In the last two months we have generated 8 constructs which delete large regions at the 5' and 3' ends of the promoter. These constructs have been used in new reporter assays using a dual luciferase assay system (Promega) to normalize for transfection. This system is superior to the previously used LacZ system.
- 4) Reporter studies in MCF7 (breast) and 293T (embryonic kidney) cells have determined that the basal activity of the BRCA2 promoter is controlled by cis-acting elements in a region between 500bp 5' of the transcriptional start site (TSS) to 400bp 3' to the TSS. The region 3' to the TSS is critical for promoter activity. This region is known to contain GC boxes that bind SP1 transcription factors. Thus we will test the involvement of SP1 by observing the effects of placing inactivating mutations in the GC boxes on promoter activity. A 500bp region located 1500bp 5' of the TSS also correlates with activity in 293T cells. This region may contain a binding site for a breast or kidney specific activator of BRCA2. Further deletion studies of this region will be undertaken in order to identify the specific controlling element.

5) In order to identify the controlling elements within the 900bp basal activating region a series of 10 deletion constructs have been generated. These constructs contain the basal region with 100bp deletion from either the 5' or 3' end. No reporter assays have yet been performed.

6) Three new constructs which specifically delete the 3' region of the promoter containing putative enhancer and silencer elements are being generated. The goal is to assess the putative effect of the enhancers on BRCA2 expression.

#### Future Experiments

1) The 3' region of the basal promoter will be intensively studied to identify GC boxes or other sites that regulate BRCA2 expression. The involvement of critical sites will be verified by mutagenesis and electrophoretic mobility shift assays.

2) The enhancer, silencer, and 5' tissue specific activator regions will be similarly studied.

3) Microdeletions of the basal activating region will be used to identify other critical regulatory elements.

4) Tissue specificity will be further studied using cell lines from other tissues such as ovary, prostate, and pancreas.

5) The effect of exogenous agents on BRCA2 expression will be assessed. For instance, cell lines containing the promoter will be exposed to 4 Gy of gamma irradiation. The influence of radiation exposure on BRCA2 expression will be measured by Northern blot of RNA from the exposed cells and by reporter assay. Other exogenous agents under study will include other forms of radiation including UV rays, IR rays, and chemicals that induce thymine dimers and other forms of radiation damage in DNA. Cellular mitogens such as interleukins and interferon will be tested, and finally genes such as activated Her2/neu and Ras that regulate cellular signalling mechanisms.